First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has imaged the first patient in its registrational Phase III 6...
Read more: First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT